Roundtable Bladder Cancer
Advertisement
The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.
The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.
The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.
The panel covers 2L treatment options for mUC post-EV/pembro, with emphasis on platinum-based chemo and targeted therapy.
The panel debates patient selection, alternative regimens, and the balance between escalation and de-escalation strategies.
The panel weighs the impact of long-term survival data from the EV-302 trial, with significant improvements in OS.
In the final part of this roundtable, Drs. Koshkin and Grivas discuss the use of EV/pembro and which patients are eligible.
In part five of this roundtable, the panelists explore the use of ctDNA in the TOMBOLA and IMvigor011 trials.
In the fourth part of this roundtable series, the panelists discuss recent updates on bladder-sparing treatments.
In part 3 of this roundtable, the NIAGARA trial is discussed, along with cisplatin regimens and the potential of durvalumab.
In the second part of this roundtable, new trials including VOLGA and EV-304 are analyzed.
In part 1, the panelists examine the evolving treatment landscape of MIBC and NMIBC, including discussion on new trials.
The panel concludes with their forward-thinking thoughts on the impending direction of urothelial carcinoma treatment.
The panel considered the latest available data pertaining to EV, atezolizumab, erdafitinib, and other therapy options.
The panel highlighted new data released on SG, including real-world findings and relevant results from the UNITE trial.
The panel transitioned to the AMBASSADOR trial findings and other adjuvant treatment considerations for urothelial carcinoma.
The panel weighed in on treatment selection after patient progression on EV/pembrolizumab.
The panel considered treatment options for patients with mUC who are not eligible for EV/pembrolizumab.
The panel discussed how enfortumab vedotin and pembrolizumab figures to change the bladder cancer treatment landscape.
The panel conclude with their thoughts on considerations for TURBT and intravesical therapy versus chemoablation.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.